Background. Chemotherapy-induced mucositis is characterized by inflammation and
INTRODUCTION
The anti-metabolite chemotherapeutic agent, 5-Fluorouracil (5-FU), is commonly used to treat a variety of malignancies including breast and bowel cancer 1, 2 . However, its nonspecific mechanism of action results in collateral damage to enterocytes lining the small intestine and the subsequent manifestation of a condition known as mucositis. Mucositis is characterised by severe pain, nausea, bloating, diarrhoea and loss of appetite, accompanied by histological features of decreased villus length and crypt disruption 3 .
Mucositis affects up to 500,000 cancer sufferers each year 4 and severely reduces quality of life in patients undergoing chemotherapy regimens 5 . Mucositis can affect the entire gastrointestinal tract, but most commonly affects the mucosa of the mouth and small intestine. Chemotherapy with agents such as 5-FU induces enterocyte apoptosis combined with decreased gut barrier function, allowing translocation of pathogenic bacteria and endotoxins into the bloodstream. This can result in systemic infection and sometimes death.
Mucositis can be so severe that chemotherapy regimens must be restructured, or in some cases discontinued, altering patient prognosis 5 .
There are currently no definitive treatments for chemotherapy-induced mucositis, although agents have been identified that are able to combat specific features of mucositis pathogenesis. Although reduced mucositis severity has been reported following treatment with keratinocyte growth factor 1 [6] [7] [8] , few other agents have progressed beyond the experimental stage. Recently, a somewhat disparate group of naturally-sourced agents have demonstrated improvements in mucositis symptomatology in the experimental setting. These include a whey-derived growth factor extract 9 , plant extracts such as Grape Seed Extract 10, 11 and Iberogast 12 , animal-sourced oils such as Emu Oil [13] [14] [15] [16] and Lyprinol 17 and certain Mashtoub-4 probiotics 18 . However, despite the effectiveness of these compounds, the need to pursue alternative treatment modalities still remains.
Purine and pyrimidine nucleotides are vital in structural, metabolic, energetic and regulatory processes and are particularly important in rapidly-dividing cells such as intestinal enterocytes [19] [20] [21] where they are essential for proliferation and in the repair process 19 .
Endogenous supply of nucleotides is maintained through de novo synthesis and the salvage pathway 21 . Cells lining the intestinal epithelium lack significant capacity for de novo synthesis of such nucleotides and require an exogenous source of purine and pyrimidine bases 20, [22] [23] [24] . Several studies have described the ability of exogenous nucleotides to either ameliorate intestinal damage or to promote repair 21, 25, 26 . However, specific effects on chemotherapy-induced mucositis have not yet been described.
Accordingly, the present study investigated an orally administered, yeast-derived nucleotide preparation termed Nucleoforce F0328, for its potential to ameliorate 5-FU-induced intestinal mucositis in rats.
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METHODS
Nucleoforce
Nucleoforce F0328, a nucleotide preparation derived from yeast, was provided by Bioiberica S.A., Barcelona, Spain. It is a beige powder that is readily soluble in water (15%).
Nucleoforce was prepared as an aqueous stock solution (26.25mg/ml) and aliquoted into individual Eppendorf tubes (1.5ml) before storage at -80C.
Animal Study
Female 
Daily Metabolic Data and Disease Activity Index
Body weight, food and water intake, and fecal and urine output were monitored and measured daily. The severity of mucositis was assessed daily, using a disease activity index (DAI), which scored body weight loss, rectal bleeding, stool consistency, and overall general condition of the animal, increasing in severity on a scale of 0-3 for each parameter, which was totalled to achieve an overall DAI, as described previously 28, 29 . Overall condition was determined by (1) mobility/agility: healthy rats were considered quite active, whereas rats affected by 5-FU characteristically became very weak and feeble, sitting hunched with very little movement and (2) fur: healthy rats were well-groomed with fur flat to the body, whereas 5-FU-injected rats became scruffy in appearance, with ruffled fur.
Sucrose Breath Test
The sucrose breath test (SBT) was performed on day 8 immediately prior to sacrifice as a non-invasive measure of small intestinal brush-border disaccharidase activity 30 . Following an overnight fast, rats were gavaged with 1ml of an aqueous sucrose solution (0.25g/ml) labelled with the non-radioactive isotope 13 C. Rats were then placed in sealed plastic containers for 2 minutes, at which time a 10ml sample of breath was collected into an evacuated tube. Breath 
Tissue collection
Following sacrifice by CO 2 asphyxiation and cervical dislocation on day 8, the gastrointestinal tract of each animal was removed, measured, emptied of contents and weighed. Following measurements, 2cm segments of small intestinal tract (jejunum, jejunumileum junction (JI) and ileum) were collected and placed in 10% buffered formalin for histological analysis. Subsequently, segments (4cm) directly adjacent to the corresponding histological samples were snap-frozen in liquid nitrogen for biochemical analysis. Samples were stored at -80 0 C until prepared for analysis by homogenization in 10mM phosphate buffer. The visceral organs (thymus, heart, spleen, liver, kidneys and lungs) were removed, weighed and discarded.
Histological Analyses
Tissue samples were transferred from 10% buffered formalin into a 70% ethanol solution 24
hours post-collection. Specimens were then routinely processed and embedded in paraffin wax and 4µm sections were prepared and stained with haematoxylin and eosin (H&E). The overall histological damage severity was assessed by a semi-quantitative scoring system, as per Howarth et al. 9 in a blinded fashion, using an Olympus CX-13 light microscope (Olympus, Tokyo, Japan). The parameters assessed were: Villus/crypt ratio, enterocyte disruption, reduction in goblet cell numbers, crypt disruption, polymorphonuclear cell infiltration, oedema of the submucosa and thickening of the muscularis externa. Each parameter was allocated a score between 0 (no damage) to 3 (extreme damage). Small intestinal villus height and crypt depth were measured in the jejunum and ileum (40 villi and 40 crypts per section) using a light microscope (Olympus BH-2, Tokyo, Japan) and digital camera (Sony, Tokyo, Japan) using analysis imaging software (Version 5.1, Olympus, Tokyo, Japan) 9 .
Myeloperoxidase (MPO) activity
Myeloperoxidase levels in the small intestine were determined as an indicator of neutrophil infiltration, and hence, acute inflammation, using techniques described by Howarth et al. 9 Briefly, jejunal tissue samples were centrifuged at 13000g for 10 min, after which the supernatant was discarded and the tissue homogenate re-suspended in 0.5% hexadecyltrimethyl ammonium bromide (HTAB). After vortexing for 2 min, samples were Mashtoub-8 re-centrifuged, at 5000g for 2 min. The supernatants were then aliquoted into 96 well plates.
After the addition of o-dianisidine reagent, the change in absorbance was measured at 450nm
on an ELISA plate reader (Sunrise Microplate Absorbance Reader, Tecan Austria GmbH, Grödig, Austria).
Statistical Analyses
Statistical analyses were performed with SPSS (Version 15, Chicago, USA). Daily metabolic data were analysed and compared both within and between groups using an ANOVA with a
Holme's post hoc test. Histological severity scores were analysed with a Kruskal Wallis test and a Bonferroni post hoc test and expressed as median (range). The remaining data were analysed by a one-way ANOVA with a Tukey post hoc test and expressed as mean ± standard error of the mean (SEM). p<0.05 was considered significant.
Mashtoub-9
RESULTS
Metabolic data
Prior to administration of 5-FU or saline, body weight increased in all animals from days 0-4 (p<0.05), with no significant differences between groups (p>0.05; Figure 1 ). Rats injected with 5-FU displayed significantly less bodyweight on days 6-8, compared with normal controls, including those treated with Nucleoforce (p<0.001; Figure 1 ). Rats were fasted on days 0, 5 and 8 for the sucrose breath test, accounting for the observed weight loss (Figure 1 ).
In normal rats, Nucleoforce did not significantly affect metabolic parameters compared to normal controls (p>0.05; Table 1 ). Food intake and faecal output were significantly decreased by 5-FU injection, compared with normal controls (p<0.05; Table 1 ), whilst water intake and urine output remained unchanged. Nucleoforce did not improve food intake and faecal output in 5-FU-injected rats compared to 5-FU controls (p>0.05; Table 1 ).
Sucrose breath test
Brush border sucrase activity was used as an indicator of the health and maturity of epithelial cells which line the small intestine, assessed using the SBT. On day 8, 72 hours post-5-FU injection, the percentage cumulative dose of 13 C (%CD) at 75, 90, 105 and 120 minutes remained unchanged following Nucleoforce treatment in normal rats compared to normal controls (p>0.05; Figure 2 ). In 5-FU-injected rats, %CD was significantly decreased compared to normal controls (p<0.001; Figure 2 ). %CD was not improved by Nucleoforce in 5-FU-injected rats compared to 5-FU controls (Figure 2 ; p>0.05).
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Visceral organ weights
Organ weights were expressed as a proportion of body weight. Heart, liver, spleen, thymus, lungs, right kidney and left kidney weights were not significantly affected by Nucleoforce treatment in normal rats compared to normal controls (p>0.05; Table 2 ). Spleen weight was significantly decreased by 5-FU administration compared to normal controls (p<0.05).
However, 5-FU did not significantly alter other visceral organ weights. Nucleoforce treatment in 5-FU-injected rats resulted in significantly decreased spleen weights compared to 5-FU controls (p<0.05; Table 2 ).
Intestinal organ weights and lengths
In normal rats, Nucleoforce did not significantly affect intestinal organ weights or lengths compared to normal controls (p>0.05; Table 3 ). 5-FU significantly decreased jejuno-ileum weights compared to normal controls (p<0.001; Table 3 ). Neither 5-FU nor Nucleoforce affected other intestinal organ weights or lengths (p>0.05; Table 3 ).
Histological severity scoring
In normal rats, Nucleoforce treatment did not significantly affect histologically-assessed severity scores in the jejunum (p>0.05), however, Nucleoforce increased severity scores in the ileum compared to normal controls (p=0.043; Table 4 ). 5-FU administration significantly increased severity scores in both the jejunum and ileum compared to normal controls (p<0.05). Importantly, however, Nucleoforce treatment significantly decreased severity scores in the jejunum (p=0.039) and ileum (p=0.041) of 5-FU-injected rats compared to 5-FU controls (Table 4) .
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Small intestinal histology
Jejunal villus height and crypt depth were not significantly affected by Nucleoforce treatment in normal rats compared to normal controls (p>0.05; Figure 3a) . However, in the ileum, Nucleoforce treatment significantly decreased villus height (p<0.001), with no effect on crypt depth (p>0.05), compared to normal controls (Figure 3b ). 5-FU administration significantly decreased villus height and crypt depth in the jejunum (villus height, p<0.001; crypt depth, p<0.05; Figure 3a ) and ileum (p<0.001; Figure 3b ) compared to normal controls. In 5-FUinjected rats, Nucleoforce treatment failed to normalise villus height and crypt depth measurements compared to 5-FU controls (p>0.05).
Myeloperoxidase (MPO) activity
In normal rats, Nucleoforce did not significantly affect jejunal MPO activity compared to normal controls (Figure 4 ; p>0.05). MPO activity was significantly increased in the jejunum of 5-FU-injected rats compared to normal controls (p<0.001; Figure 4 ). In 5-FU-injected rats, Nucleoforce treatment did not significantly impact MPO activity compared to 5-FU controls (p<0.05; Figure 4 ).
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DISCUSSION
The present study determined the effects of the nucleotide preparation known as Nucleoforce F0328 on a rat model of chemotherapy-induced mucositis. Nucleoforce, at a daily bolus dose of 175 mg/kg, only minimally improved selected indicators of mucositis, extending primarily to an improvement in food intake with a partial attenuation of body weight loss associated with chemotherapy. Nevertheless, Nucleoforce reduced the severity of small intestinal damage as measured by the histological severity score in both the jejunum and ileum.
However, other parameters associated with 5-FU induced mucositis were not significantly affected by Nucleoforce.
In the current study, Nucleoforce primarily decreased injury in the proximal small intestine, as measured by the histological severity score, although there were no significant effects on villus height and crypt depth. Data are expressed as mean (myeloperoxidase activity; units per milligram; U/mg) ± SEM. *** indicates p<0.001 compared to saline + water.
